StreetInsider.com News Articles

Freedom Capital Starts Pulse Biosciences (PLSE) at Buy

Wed, 09 Sep 2026 06:14:38 -0400

Freedom Capital analyst Keith Hinton initiates coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating and a price target of $73.00.

The analyst comments "We initiate coverage of Pulse Biosciences (PLSE) with a BUY rating and $73 price target. Our bullish outlook is driven by several factors: (1) the AF ablation market is large, growing and disruptable, and we see nsPFA as a potentially significant disruptor; (2) PLSE has a prudent strategy, strong leadership and enough cash to fund operations through its most important catalyst, and; (3) if NANOPULSE-AF data in ~2Q27 is in-line with our expectations, we think there

Freedom Capital Starts Pulse Biosciences (PLSE) at Buy

Wed, 09 Sep 2026 06:14:38 -0400

Freedom Capital analyst Keith Hinton initiates coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating and a price target of $73.00.

Form 4 PULSE BIOSCIENCES, INC. For: Aug 26 Filed by: Teplitsky Liane Rae

Fri, 28 Aug 2026 19:49:00 -0400

si-local-file:///var/storage/secattach/20260828/26999377.html

Form 4 PULSE BIOSCIENCES, INC. For: Aug 26 Filed by: Teplitsky Liane Rae

Fri, 28 Aug 2026 19:49:00 -0400

si-local-file:///var/storage/secattach/20260828/26999377.html

Form 4 PULSE BIOSCIENCES, INC. For: Apr 08 Filed by: Teplitsky Liane Rae

Fri, 28 Aug 2026 19:45:00 -0400

si-local-file:///var/storage/secattach/20260828/26999374.html

Form 4 PULSE BIOSCIENCES, INC. For: Apr 08 Filed by: Teplitsky Liane Rae

Fri, 28 Aug 2026 19:45:00 -0400

si-local-file:///var/storage/secattach/20260828/26999374.html

Form 3 PULSE BIOSCIENCES, INC. For: Apr 08 Filed by: Teplitsky Liane Rae

Fri, 28 Aug 2026 19:42:00 -0400

si-local-file:///var/storage/secattach/20260828/26999372.html

Form 3 PULSE BIOSCIENCES, INC. For: Apr 08 Filed by: Teplitsky Liane Rae

Fri, 28 Aug 2026 19:42:00 -0400

si-local-file:///var/storage/secattach/20260828/26999372.html

Form 4 PULSE BIOSCIENCES, INC. For: Feb 03 Filed by: Skinner Jon

Fri, 28 Aug 2026 19:17:00 -0400

si-local-file:///var/storage/secattach/20260828/26999355.html

Form 4 PULSE BIOSCIENCES, INC. For: Feb 03 Filed by: Skinner Jon

Fri, 28 Aug 2026 19:17:00 -0400

si-local-file:///var/storage/secattach/20260828/26999355.html

Form 3 PULSE BIOSCIENCES, INC. For: Feb 03 Filed by: Skinner Jon

Fri, 28 Aug 2026 19:15:00 -0400

si-local-file:///var/storage/secattach/20260828/26999352.html

Form 3 PULSE BIOSCIENCES, INC. For: Feb 03 Filed by: Skinner Jon

Fri, 28 Aug 2026 19:15:00 -0400

si-local-file:///var/storage/secattach/20260828/26999352.html

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 18 Aug 2026 07:00:00 -0400

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on August 13, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 18 Aug 2026 07:00:00 -0400

Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 18 Aug 2026 07:00:00 -0400

Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 18 Aug 2026 07:00:00 -0400

Pulse has awarded inducement options to five new employees to purchase, in aggregate, up to

Needham Starts Pulse Biosciences (PLSE) at Buy

Mon, 17 Aug 2026 06:34:33 -0400

Needham analyst Mike Matson initiates coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating and a price target of $58.00.

The analyst comments "PLSE has developed a differentiated next-generation pulse field ablation (PFA) platform technology, Nanosecond Pulsed Field Ablation (nsPFA). PLSE is targeting three applications of nsPFA: cardiac catheter ablation ($3.0B US, $8.0B global), cardiac surgical ablation ($1.8B US, $6.0B global), and benign thyroid lesion ablation ($1.3B US, $2.8B global). Early clinical results have been positive and PLSE is now running two pivotal studies. We expect clinical data and/or a partnership announcement to drive PLSE shares higher ahead of key

Needham Starts Pulse Biosciences (PLSE) at Buy

Mon, 17 Aug 2026 06:34:33 -0400

Needham analyst Mike Matson initiates coverage on Pulse Biosciences (NASDAQ: PLSE) with a Buy rating and a price target of $58.00.

Pulse Biosciences (PLSE) PT Raised to $43 at Canaccord

Mon, 10 Aug 2026 07:34:23 -0400

(Updated - August 10, 2026 7:34 AM EDT)

Canaccord analyst William Plovanic raised the price target on Pulse Biosciences (NASDAQ: PLSE) to $43.00 (from $32.00) while maintaining a Buy rating.

The analyst commented: 'Pulse continues to make clinical-regulatory progress towards bringing its differentiated nanosecond PFA system to market. The Q2/26 earnings call focused on these developments rather than financial performance given Pulse is a very early-stage commercial company. Discussion centered on the NANOPULSE-AF study, which surpassed its enrollment midpoint in late July (see our note here). While not a Q2 event, it is the biggest milestone and future potential catalyst of the

Pulse Biosciences (PLSE) PT Raised to $43 at Canaccord

Mon, 10 Aug 2026 07:34:23 -0400

(Updated - August 10, 2026 7:34 AM EDT)

Canaccord analyst William Plovanic raised the price target on Pulse Biosciences (NASDAQ: PLSE) to $43.00 (from $32.00) while maintaining a Buy rating.

Pulse Biosciences (PLSE) PT Raised to $45 at Mizuho

Mon, 10 Aug 2026 07:13:28 -0400

Mizuho analyst Anthony Petrone raised the price target on Pulse Biosciences (NASDAQ: PLSE) to $45.00 (from $30.00) while maintaining a Outperform rating.

Form 8-K PULSE BIOSCIENCES, INC. For: Aug 06

Thu, 06 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260806/26885401.html

Form 8-K PULSE BIOSCIENCES, INC. For: Aug 06

Thu, 06 Aug 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260806/26885401.html

Form 424B5 PULSE BIOSCIENCES, INC.

Thu, 06 Aug 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26885393.html

Form 424B5 PULSE BIOSCIENCES, INC.

Thu, 06 Aug 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26885393.html